Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Patient meets protocol criteria for diagnosis of IBS-C, abdominal pain, abdominal bloating and abdominal girth~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has both clinically significant findings and unexplained clinically significant alarm symptoms~* Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 290 μg linaclotide (Type: EXPERIMENTAL): Linaclotide Oral, once daily
- Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo Oral, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).